United States - English - NLM (National Library of Medicine)

mylan institutional inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does n

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 25 mg - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, usp, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril tablets, usp may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets, usp are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets, usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not requir

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, usp consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril tablets, usp may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets, usp are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets, usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 25 mg - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets, are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. captopril tablets, are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. captopril tablets, are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus and retinopathy. captopril tablets, usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). in considering use of captopril tablets, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see  warnings: head and neck angioedema  and intestinal angioedema ). captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). do not co-administer aliskiren with captopril tablets in patients with diabetes (see precautions, drug interactions ). captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer captopril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see precautions, drug interactions ).

United States - English - NLM (National Library of Medicine)

redpharm drug inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 15 mg - captopril tablets are indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most control

United States - English - NLM (National Library of Medicine)

rebel distributors corp - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 25 mg - captopril tablets are indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most control

United States - English - NLM (National Library of Medicine)

doh central pharmacy - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 50 mg - captopril tablets are indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most control

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 25 mg - captopril tablets are indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most control

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - captopril 25 mg - captopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. the blood pressure lowering effects of captopril and thiazides are approximately additive. this fixed combination drug may be used as initial therapy or substituted for previously titrated doses of the individual components. when captopril and hydrochlorothiazide are given together it may not be necessary to administer captopril in divided doses to attain blood pressure control at trough (before the next dose). also, with such a combination, a daily dose of 15 mg of hydrochlorothiazide may be adequate. treatment may, therefore, be initiated with captopril and hydrochlorothiazide tablets 25 mg/15 mg once daily. subsequent titration should be with additional doses of the components (captopril, hydrochlorothiazide) as single agents or as captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg, or 50 mg/25 mg (see dosage and administration). in using captopril and hydrochlorothiazide, consideration should be give

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - mercaptopurine (unii: e7wed276i5) (mercaptopurine anhydrous - unii:pkk6muz20g) - mercaptopurine 50 mg - mercaptopurine tablets are indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy maintenance regimen. none. mercaptopurine tablets can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . pregnant women who receive mercaptopurine have an increased incidence of miscarriage and stillbirth (see data) . advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. women receiving mercaptopurine in the first trimester of pregnancy have an increased incidence of miscarriage; the risk of malformation in offspring surviving first trimester exposure is not known. in a series of 28 women receiving mercaptopurine after the first trimester of pregnancy, 3 mothers died prior to delivery, 1 delivered a stillborn child, and 1 aborted; there were no cases of macroscopically abnormal fetuses. mercaptopurine was embryo-lethal and teratogenic in several animal species (rat, mouse, rabbit, and hamster) at doses less than the recommended human dose. there are no data on the presence of mercaptopurine or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with mercaptopurine tablets and for 1 week after the last dose. mercaptopurine tablets can cause fetal harm when administered to pregnant women [see use in specific populations (8.1)] . verify the pregnancy status in females of reproductive potential prior to initiating mercaptopurine tablets [see use in specific populations (8.1)] . advise females of reproductive potential to use effective contraception during treatment with mercaptopurine tablets and for 6 months after the last dose. based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with mercaptopurine tablets and for 3 months after the last dose [see nonclinical toxicology (13.1)] . based on findings from animal studies, mercaptopurine tablets can impair female and male fertility [see nonclinical toxicology (13.1)] . the long-term effects of mercaptopurine on female and male fertility, including the reversibility have not been studied. safety and effectiveness of mercaptopurine tablets have been established in pediatric patients. use of mercaptopurine tablets in pediatrics is supported by evidence from the published literature and clinical experience. symptomatic hypoglycemia has been reported in pediatric patients with all receiving mercaptopurine. reported cases were in pediatrics less than 6 years of age or with a low body mass index. clinical studies of mercaptopurine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or another drug therapy. use the lowest recommended starting dosage for mercaptopurine tablets or increase the dosing interval to every 36-48 hours in patients with renal impairment (clcr less than 50 ml/min). adjust the dose to maintain absolute neutrophil count (anc) at a desirable level and for adverse reactions [see dosage and administration (2.3)] . use the lowest recommended starting dosage for mercaptopurine tablets in patients with hepatic impairment. adjust the dose to maintain absolute neutrophil count (anc) at a desirable level and for adverse reactions [see dosage and administration (2.3)] .